Biotron Limited (BITRF)

-96.97% (1Y)

Market Cap	1.74M
Revenue (ttm)	1.12M
Net Income (ttm)	-876.35K
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	5
Open	0.0027
Previous Close	0.0011
Day's Range	0.0011 - 0.0027
52-Week Range	0.0011 - 0.0497
Beta	-0.70
RSI	6.19
Earnings Date	Aug 27, 2025

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: BITRF

Financial Performance

In 2024, Biotron's revenue was 1.65 million, an increase of 14.94% compared to the previous year's 1.43 million. Losses were -3.44 million, -1.61% less than in 2023.

Financial numbers in AUD